Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review
L. N. Toksvang, K. Schmiegelow, M. S. Schmidt, S. Arup, R. H. Larsen, T. L. Frandsen, C. U. Rank
This review assesses hepatotoxicity risks of 6-thioguanine treatment in ALL and IBD patients, finding that lower doses (≤12 mg/m2/day) are associated with minimal hepatotoxicity.
bioRxiv · Jan 31, 2019Pharmacology & Toxicology